1. MarketsandMarkets Presents Biosimilars Market worth $6.22 Billion by 2020 http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

2. The report “Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020” analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW). Browse 84 market data tables and 39 figures spread through 162 pages and in-depth TOC on “Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020“ http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

3. Early buyers will receive 10% customization on this report. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

4. The global biosimilars market is expected to reach $6.22 Billion by 2020 from $2.29 Billion in 2015, at a CAGR of 22.1% from 2015 to 2020. The report segments the market on the basis of product, application, and region. Among various product types, the recombinant nonglycosylated protein segment is expected to account for the largest share of the market in 2015. However, the recombinant glycosylated protein segment is expected to grow at the highest CAGR during the forecast period. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

5. A number of factors such as growing pressure to curtail healthcare expenditure, growing demand of biosimilar drugs due to their cost effectiveness, rising incidences of various diseases, increasing number of off-patented drugs, positive outcome in the ongoing clinical trials, and rising demand for biosimilars in different therapeutic applications such as rheumatoid arthritis and blood disorders are propelling the growth of the global market. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

6. On the other hand, high manufacturing complexities and costs, stringent regulatory requirements in countries, and innovative strategies by biologic drug manufacturers to restrict entry of new players are restricting the growth of the global market. Geographically, the global biosimilars market is dominated by Europe, followed by Asia-Pacific, Rest of the World (RoW), and North America. However, the Asia-Pacific region is likely to witness the highest growth rate during the forecast period. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

7. Factors such as developing healthcare infrastructure, presence of a large patient population, increasing funding/investments for the development of biosimilars, and growing focus of both international and domestic players on emerging Asia-Pacific countries are stimulating the growth of the market in this region. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

8. The key players in the global market include Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories (India), Biocon Limited (India), Mylan, Inc. (U.S.), Amgen (U.S.), Celltrion Inc. (South Korea), Roche Diagnostics (Switzerland), and Merck KGaA (Germany). http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

9. Contact Us Contact: Mr. Rohan Markets and Markets UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India 1-888-600-6441 Email: sales@marketsandmarkets.com http://www.linkedin.com/company/marketsandmarkets http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

10. About MarketsandMarkets MarketsandMarkets is the world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html